Loading
T2 Biosystems, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Gibbs Michael Terrence, was filed 11 Apr 2022.
T2 Biosystems, Inc.: what insiders have been doing
This page follows insider dealings at T2 Biosystems, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. T2 Biosystems, Inc. has had no insider filing for more than a year; the last one goes back to 17 September 2024.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
90
Thresholds
n/a
Buy Volume
€33,786
7 ops. · all time
Sell Volume
€35,834
15 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$7.2M
Gross profit-US$8.2M-114% margin
EBITDA-US$43.9M-610% margin
Net income-US$50.1M-696.2% margin
Valuation
Beta7.84
Balance sheet & cash
Market capUS$14k
Total debtUS$49.5M
Free Cash Flow-US$48.3M
Profitability & ownership
ROA-84.9%
% insiders5.4%
% institutions0.0%
Last declaration on 17 September 2024
Declarations90 total
55 shares@ US$2.42100.0% of flowCommon StockSEC:0000950170-24-107349:0
1,716,048 sharesCommon StockSEC:0001415889-24-013055:0
648,139 sharesCommon StockSEC:0001415889-24-012484:0
682,036 sharesCommon StockSEC:0001415889-24-010906:0
29 sharesCommon StockSEC:0000950170-24-021243:0
67 sharesCommon StockSEC:0000950170-24-021248:0
29 sharesCommon StockSEC:0000950170-24-021242:0
40 sharesCommon StockSEC:0000950170-24-017070:0
40 sharesCommon StockSEC:0000950170-24-017073:0
160 sharesCommon StockSEC:0000950170-24-017071:0
13 sharesCommon StockSEC:0000950170-24-017069:0
335,947 sharesCommon StockSEC:0001415889-24-004167:0
1,333 sharesCommon StockSEC:0000950170-23-066386:0
33 sharesCommon StockSEC:0000950170-23-066398:0
7 sharesCommon StockSEC:0000950170-23-054380:0
2,300 sharesCommon StockSEC:0000950170-23-052935:0
2,600 sharesCommon StockSEC:0000950170-23-052934:0
2,300 sharesCommon StockSEC:0000950170-23-052933:0
2,300 sharesCommon StockSEC:0000950170-23-052931:0
2,300 sharesCommon StockSEC:0000950170-23-052930:0
2,300 sharesCommon StockSEC:0000950170-23-052936:0
2,300 sharesCommon StockSEC:0000950170-23-052932:0
2,391,981 shares@ €0.18249.9% of flowCommon StockSEC:0001209191-23-050864:0
2,156,717 shares@ €0.18999.3% of flowCommon StockSEC:0001209191-23-050732:0
99,979 shares@ €0.2360.5% of flowCommon StockSEC:0001209191-23-050677:0
25 of 90 declarations
About T2 Biosystems, Inc.
T2 Biosystems, Inc. is a United States-based in vitro diagnostics company listed on the NASDAQ Capital Market under the ticker TTOO. Headquartered in Lexington, Massachusetts, and incorporated in Delaware in 2006, the company operates in a highly specialized part of healthcare diagnostics focused on rapid direct-from-blood detection of pathogens and biomarkers, with a particular emphasis on bloodstream infections and sepsis.
The company’s core technology is its proprietary T2 Magnetic Resonance (T2MR®) platform, which is designed to identify targets directly from whole blood without waiting for a positive culture. T2 Biosystems’ commercial portfolio centers on the T2Dx Instrument, the T2Candida Panel, and the T2Bacteria Panel. Management also highlights a development pipeline aimed at broadening the addressable market through additional pathogen species, antibiotic-resistance markers, and future applications such as Lyme disease testing.
Read moreShow less
From an investor’s perspective, T2 Biosystems is positioned in a niche where speed, accuracy, and earlier clinical decision-making can materially affect outcomes and hospital economics. The strategic appeal of the platform is tied to faster treatment selection, better antibiotic stewardship, and the potential to reduce delays associated with conventional culture-based testing. At the same time, the company faces the realities of a competitive diagnostics market, where commercialization scale, reimbursement, regulatory execution, and balance-sheet strength are critical differentiators.
Geographically, the business remains primarily U.S.-anchored, but it has also pursued international commercialization through distributors. Recent company communications point to sales of T2Dx instruments into Europe, broader commercial expansion across Europe and Asia, and continued global shipments of sepsis tests. Recent highlights include preliminary fourth-quarter and full-year 2024 results announced in January 2025, along with ongoing efforts to strengthen commercial execution, support manufacturing and supply-chain operations, and advance product development programs. For equity investors, TTOO therefore represents a small-cap diagnostics story with meaningful technology optionality, but also elevated execution and financing risk typical of an emerging molecular diagnostics platform.
